Spyre Therapeutics, Inc. short interest in 2026
In 2026, Spyre Therapeutics, Inc.'s disclosed short interest ran from 12.98% of shares outstanding on 15 Jan 2026 to 13.76% on 15 Sep 2026, a change of +0.78 percentage points. The year's high was 15.71% on 30 Jun 2026 and its low 12.56% on 13 Feb 2026, averaging 13.76% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.29 days on 30 Jan 2026. Full history: Spyre Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 12.98% (15 Jan 2026)
- End of year
- 13.76% (15 Sep 2026)
- Change
- +0.78 pp
- High
- 15.71% (30 Jun 2026)
- Low
- 12.56% (13 Feb 2026)
- Average
- 13.76%
- Highest days to cover
- 20.29 (30 Jan 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 12.98% | 13.89 | |
| 30 Jan 2026 | 12.86% | 20.29 | |
| 13 Feb 2026 | 12.56% | 14.87 | |
| 27 Feb 2026 | 12.71% | 12.42 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 12.73% | 13.99 | |
| 31 Mar 2026 | 13.29% | 11.48 | |
| 15 Apr 2026 | 14.86% | 7.35 | results (8-K) |
| 30 Apr 2026 | 14.07% | 10.04 | |
| 15 May 2026 | 14.30% | 10.44 | 10-Q filed, results (8-K) |
| 29 May 2026 | 14.54% | 15.47 | |
| 15 Jun 2026 | 14.53% | 10.83 | |
| 30 Jun 2026 | 15.71% | 5.56 | |
| 15 Jul 2026 | 14.40% | 9.03 | |
| 31 Jul 2026 | 13.77% | 13.52 | |
| 14 Aug 2026 | 13.33% | 15.95 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 13.45% | 9.69 | |
| 15 Sep 2026 | 13.76% | 11.58 |
See also: Spyre Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.